Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis
Abstract Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded confli...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-022-02813-w |
| _version_ | 1811257203694239744 |
|---|---|
| author | Dan Zhang Jingting Liu Mengxia Zheng Chunyan Meng Jianhua Liao |
| author_facet | Dan Zhang Jingting Liu Mengxia Zheng Chunyan Meng Jianhua Liao |
| author_sort | Dan Zhang |
| collection | DOAJ |
| description | Abstract Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment. |
| first_indexed | 2024-04-12T17:52:49Z |
| format | Article |
| id | doaj.art-840b6a7fde6a4e0db92c7cd5a25b6d3f |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-12T17:52:49Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-840b6a7fde6a4e0db92c7cd5a25b6d3f2022-12-22T03:22:26ZengBMCWorld Journal of Surgical Oncology1477-78192022-10-0120111310.1186/s12957-022-02813-wPrognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysisDan Zhang0Jingting Liu1Mengxia Zheng2Chunyan Meng3Jianhua Liao4Department of Anesthesiology, Zhejiang HospitalDepartment of Health Management, Sir Run Run Shaw International Medical CentreDepartment of Surgery, Zhejiang HospitalDepartment of Surgery, Zhejiang HospitalDepartment of Surgery, Zhejiang HospitalAbstract Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment.https://doi.org/10.1186/s12957-022-02813-wCD155CancerPrognosisBiomarkerMeta-analysis |
| spellingShingle | Dan Zhang Jingting Liu Mengxia Zheng Chunyan Meng Jianhua Liao Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis World Journal of Surgical Oncology CD155 Cancer Prognosis Biomarker Meta-analysis |
| title | Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis |
| title_full | Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis |
| title_fullStr | Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis |
| title_full_unstemmed | Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis |
| title_short | Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis |
| title_sort | prognostic and clinicopathological significance of cd155 expression in cancer patients a meta analysis |
| topic | CD155 Cancer Prognosis Biomarker Meta-analysis |
| url | https://doi.org/10.1186/s12957-022-02813-w |
| work_keys_str_mv | AT danzhang prognosticandclinicopathologicalsignificanceofcd155expressionincancerpatientsametaanalysis AT jingtingliu prognosticandclinicopathologicalsignificanceofcd155expressionincancerpatientsametaanalysis AT mengxiazheng prognosticandclinicopathologicalsignificanceofcd155expressionincancerpatientsametaanalysis AT chunyanmeng prognosticandclinicopathologicalsignificanceofcd155expressionincancerpatientsametaanalysis AT jianhualiao prognosticandclinicopathologicalsignificanceofcd155expressionincancerpatientsametaanalysis |